Immunogenicity of SARS-CoV-2 Epitope Identified by Immune Epitope Database & Analysis (IEDB) Server

Abstract

In 2020, The World Health Organisation (WHO) has declared a pandemic due to the outbreak of a novel coronavirus 2019 (COVID-19), which is caused by the SARS-CoV-2 virus. It is imperative to stop the virus from spreading and to treat individuals who are affected effectively. Consequently, in order to meet the demands of the global community in fighting the pandemic, vaccine development must go quickly, enable mass production, be cost-effective, safe, and extremely accurate. The current vaccine takes longer to create and is more expensive since it is made using a traditional method that primarily involves live-attenuated whole-pathogen vaccines. A recent development in vaccine manufacture, reverse vaccinology makes more use of bioinformatics tools and computational techniques. Furthermore, it has been demonstrated in previous relevant studies that the use of bioinformatics tools in modern vaccine production yields better results than traditional vaccine production.